

Dosing
1° Endpoint (EASI-50)
End of Study
TCS Cream, as Needed
Lebrikizumab
250 mg Single Dose (+ 2 Pbo Doses)
+ TCS Cream
Lebrikizumab
125 mg Single Dose (+ 2 Pbo Doses)
+ TCS Cream
Lebrikizumab
125 mg Q4Wk (3 Doses)
+ TCS Cream
Placebo SC (3 Doses)
+ TCS Cream
TCS 2x Daily to Lesional Skin
TCS Run-in
(All Patients)
TCS Cream 2x Daily to Lesional Skin
Screening Visit
Assess Eligibility
for Entry to the
Run-in Period
End of Run-in Visit
Assess Eligibility
for Randomization
to Study Drug
D-14
D-1
Wk 0
Wk 4
Wk 8
Wk 12
Wk 20
Run-in Period (2 Weeks)
Treatment Period (12 Weeks)
Safety Follow Up (8 Weeks)

FIG. 1



Proportion of Patients (%)
90
80
70
60
50
40
30
20
10
0
0
1
4
6
8
12
Week
Treatment Group
Lebri 250 mg Single + TCS BID
Lebri 125 mg Single + TCS BID
Lebri 125 mg Q4W + TCS BID
Placebo + TCS BID

FIG. 2A



Proportion of Patients (%)
90
80
70
60
50
40
30
20
10
0
0
1
4
6
8
12
Week
Treatment Group
Lebri 250 mg Single + TCS BID
Lebri 125 mg Single + TCS BID
Lebri 125 mg Q4W + TCS BID
Placebo + TCS BID

FIG. 2B



Treatment Group
Lebri 250 mg SD + TCS BID
Lebri 125 mg SD + TCS BID
Lebri 125 mg Q4W + TCS BID
Placebo + TCS BID
Proportion of Patients (%)
35%
30%
25%
20%
15%
10%
5%
0%
0
4
8
12
Week

FIG. 2C



Patients (%)
0
20
40
60
80
100
Baseline
Week 1
Week 4
Week 6
Week 8
Week 12
Week 16
Week 20
Treatment Group
Lebri 250 mg SD + TCS BID
Lebri 125 mg SD + TCS BID
Lebri 125 mg Q4W + TCS BID
Placebo + TCS BID

FIG. 3A



Patients (%)
0
20
40
60
80
100
Baseline
Week 1
Week 4
Week 6
Week 8
Week 12
Week 16
Week 20
Treatment Group
Lebri 250 mg SD + TCS BID
Lebri 125 mg SD + TCS BID
Lebri 125 mg Q4W + TCS BID
Placebo + TCS BID

FIG. 3B



Treatment Group
Lebri 250 mg SD + TCS BID
Lebri 125 mg SD + TCS BID
Lebri 125 mg Q4W + TCS BID
Placebo + TCS BID
Patients (%)
0
20
40
60
80
100
Baseline
Week 1
Week 4
Week 6
Week 8
Week 12
Week 16
Week 20

FIG. 3C



Treatment Group
Lebri 250 mg SD + TCS BID
Lebri 125 mg SD + TCS BID
Lebri 125 mg Q4W + TCS BID
Placebo + TCS BID
Week 1
Week 4
Week 6
Week 8
Week 12
10
0
-10
-20
-30
-40
-50
-60
-70
-80
Percent Change in EASI
*

FIG. 4



Disease Progression
$k_{in} = (1-E_{drug})^*E_{con}{}^*k_{in0}$
R(t)
k_{out}
Tissue Repair
$R(t) = e^{logit(\frac{EASI(t)-(-0.5)}{72.5-(0.5)})}$
$EASI \in [0,72]$
$R > 0$
$k_{in0} = k_{out} \times R(t=0)$
Anti-IL13 (E_{drug})
TCS/Placebo (E_{con})
PK Model
Dose
E_{con}: Constant Over Time
$E_{drug} = \frac{E_{max} \times [drug]}{EC_{50} + [drug]}$
E_{max}
$E_{max}/2$
E_{drug}
EC_{50}
[drug]

FIG. 5



EASI75
60
40
20
0
0
28
56
84
112
140
168
Time (d)
Lebri 125 mg Q4W
Lebri 250 mg Days 1 & 15 125 mg Q4W
Lebri 250 mg Days 1 & 29 125 mg Q4W
Lebri 250 mg Load 125 mg Q4W
Lebri 500 mg Load 125 mg Q4W
Placebo

FIG. 6



EASI75
60
40
20
0
0
28
56
84
112
140
168
Time (d)
Lebri 125 mg Q4W
Lebri 250 mg Q4W
Lebri 500 mg Load
250 mg Q4W
Placebo

FIG. 7



EASI75
60
40
20
0
0
28
56
84
112
140
168
Time (d)
Lebri 125 mg Q4W
Lebri 250 mg Q8W
Lebri 500 mg Load
250 mg Q8W
Placebo

FIG. 8



EASI75
60
40
20
0
0
28
56
84
112
140
168
Time (d)
Lebri 125 mg Load 37.5 mg Q4W
Lebri 125 mg Q4W
Lebri 37.5 mg Q4W
Placebo

FIG. 9



Dosing
1° Endpoint (EASI-50)
End of Study
TCS Cream, as Needed
(All Patients)
Lebrikizumab Monotherapy
125 mg Q4Wk (3 Doses)
No TCS Cream
TCS Cream Only
2x Daily to Lesional Skin
TCS Run-in
(All Patients)
TCS Cream 2x Daily to Lesional Skin
Screening Visit
Assess Eligibility
for Entry to the
Run-in Period
End of Run-in Visit
Assess Eligibility
for Randomization
to Study Drug
D-14
D-1
Wk 0
Wk 4
Wk 8
Wk 12
Wk 20
Run-in Period (2 Weeks)
Treatment Period (12 Weeks)
Safety Follow Up (8 Weeks)

FIG. 10




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D